Marchex (MCHX) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Q3 2024 revenue was $12.6 million, down 2% year-over-year, with a net loss of $0.8 million ($0.02 per diluted share), improved from a $1.5 million loss in Q3 2023.
Adjusted EBITDA for Q3 2024 was $0.3 million, compared to $0.4 million in Q3 2023; adjusted non-GAAP loss per share remained at ($0.01) year-over-year.
The company is focused on becoming a market leader in prescriptive analytics, leveraging AI-driven products and first-party conversational data to deliver actionable insights and drive revenue for clients across multiple verticals.
Strategic initiatives include product innovation, expansion of sales and marketing teams, and channel partnerships, with ongoing infrastructure modernization through the OneStack platform to unify products and improve scalability.
Progress reported in Auto, Home Services, and Healthcare verticals, with new customer wins, expanded relationships, and a partnership with DealerOn to deploy call analytics for automotive marketing optimization.
Financial highlights
Q3 2024 revenue: $12.6 million (down 2% year-over-year); nine months: $36.2 million (down 3%).
Q3 2024 net loss: $0.8 million ($0.02 per share); nine months: $3.0 million (improved from $8.8 million loss in 2023).
Adjusted EBITDA for Q3 2024 was $0.3 million, consistent with $0.4 million in Q3 2023.
Cash and cash equivalents at September 30, 2024: $12.1 million, down from $14.6 million at year-end 2023.
Operating cash outflow for nine months ended September 30, 2024 was $2.0 million, improved from $6.1 million outflow in 2023.
Outlook and guidance
Q4 2024 revenue expected around $12 million due to seasonal call volume declines; adjusted EBITDA anticipated to be a loss of approximately $0.4 million, reflecting expense timing.
Gross margin for Q4 2024 expected to be slightly lower than Q3 due to expense timing.
2025 projected as a growth year, with Q1 2025 revenue and adjusted EBITDA expected to improve sequentially; gross margins anticipated to rise as OneStack cost savings materialize.
Sales and marketing expenses anticipated to rise modestly as marketing activities and personnel increase.
Product development and general and administrative expenses expected to remain stable or modestly lower in the near term, with longer-term increases tied to AI investments and operational expansion.
Latest events from Marchex
- AI-driven product launches and the Archenia deal set the stage for accelerated growth in 2026.MCHX
Q4 202525 Mar 2026 - Net loss narrowed and adjusted EBITDA improved as revenue is set to grow in Q3.MCHX
Q2 20242 Feb 2026 - 2025 is set for sequential growth and margin improvement, driven by new AI products and partnerships.MCHX
Q4 202424 Dec 2025 - Annual meeting to elect directors, ratify auditor, and highlight governance and compensation practices.MCHX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and performance-based compensation highlight strong governance.MCHX
Proxy Filing1 Dec 2025 - Annual proxy details director elections, voting proposals, and governance disclosures.MCHX
Proxy Filing1 Dec 2025 - Q1 2025 revenue $11.4M, net loss $2.0M, gross margin 63%, targeting $50M+ run rate.MCHX
Q1 202525 Nov 2025 - Q2 2025 saw revenue dip 3% but net income and operational efficiency improved.MCHX
Q2 202523 Nov 2025 - Q3 revenue fell, but profitability improved and Archenia acquisition aims for accelerated AI growth.MCHX
Q3 202517 Nov 2025